United States

Learn how to classify medical device pilot builds under FDA QMSR and ISO 13485, separate engineering evidence from saleable product, and handle investigational distribution.

Learn how to author compliant medical device rework instructions, determine reverification scope under ISO 13485 clause 8.3.4 and QMSR 820.3(b), and avoid undocumented fixes.

Compare FDA and EU MDR routes for reusable device life: when to claim a fixed reprocessing cycle count versus end-of-life criteria, and what aging evidence regulators accept.

A regulatory map assigning FDA establishment registration, 21 CFR 801.1 labeling, UDI labeler status, 510(k) discretion, and QMSR duties across kit assemblers and specification developers.

How to build an audit-ready medical device label durability evidence chain against validated cleaning and disinfection cycles rather than generic peel tests.

Support IVD specimen stability claims under 21 CFR 809.10 and EU IVDR Annex II by aligning labeled collection, additives, hold times, and transport with verified study configurations.

How medical device manufacturers structure customer transition plans when software reaches end of support, mapping required evidence, IMDRF milestones, and surviving duties.

FDA permits substantial equivalence claims to devices no longer marketed in the U.S. Here is how to verify eligibility, satisfy 21 CFR 807.87(f), and build evidence without physical samples.

How FDA guidance and the EU MDR decide which device models one test report covers, and which records justify an untested size or configuration.

When a laboratory may adopt an IVD manufacturer's reference interval, when CLIA requires verification or establishment, and what ISO 15189 adds only for accredited laboratories.

A practical decision guide to UDI placement across medical device packaging levels under FDA, EU MDR, and TGA rules, covering carriers, unique identifiers, and shipper exemptions.

Compare AccessGUDID and FDA's establishment registration and device listing database to choose the correct public record for device identifiers, establishments, and listing status.

Mark whether one US reagent SKU is still an ASR under 21 CFR 864.4020 and 809.30, an RUO or IUO shipment, a general-purpose reagent, or a finished IVD with performance claims.

How to determine whether a US IVD clinical protocol qualifies for 21 CFR 812.2(c)(3) exemption, requires an abbreviated or full IDE, or falls under 21 CFR Part 312 IND rules.

A practical 21 CFR 4.4 worksheet for combination product facilities after QMSR: how to verify eligibility, separate-facility rules, and current ISO 13485 or drug CGMP streamlining clauses.

A practical 21 CFR Part 4 Subpart B worksheet mapping applicant identity, 4.102 baselines and add-ons, statutory reporting clocks, and electronic routing between FAERS, eMDR, and VAERS.

A medical device RA/QA guide to records custody when changing distributors: who keeps complaint and traceability files under US, EU, and Canadian post-market rules.

How medical device RA/QA teams reconcile units, ISO symbols, and released versions across translation cycles before artwork issuance under FDA QMSR 820.45 and EU MDR GSPR 23.

When a supplier change notice omits affected lots, dates, or technical details, device QA must hold unverified product, issue an evidence request, and halt close-out until facts are verified.

A three-asset chain-of-custody crosswalk for medical device loaner exchanges: preserve serial traceability across removal, placement, and return without slot-level record overwrites.